A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > COMMENTARY
COMMENTARY
- Top Wholesalers Cut Costs to Offset Declines in Gross Profits
December 5, 2005
- Importance of Framing
November 21, 2005
- A Cluster of Diseases - Metabolic Syndrome: Reflecting Aging Society
November 7, 2005
- A Cluster of Diseases - Metabolic Syndrome:Reflecting an Aging Society -1-
October 31, 2005
- Commentary 2005 Will Be "Year 1" of Japanese Drug Industry Reorganization
October 17, 2005
- COMMENTARY 2 articles
October 10, 2005
- COMMENTARY 6 articles
September 19, 2005
- Where Will the Japanese Pharmaceutical Industry Drift? - From "The Sky Is the Limit" to the Abyss -
August 29, 2005
- COMMENTARY 5 articles
August 8, 2005
- 2 Rosai Hospitals Start Prescriptions by the Generic Name
July 25, 2005
- COMMENTARY 6 articles
July 25, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (3)
July 4, 2005
- Former Reviewers' Interviews Make OPIR Report Exciting
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)
June 20, 2005
- Special Contribution
May 16, 2005
- Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP
April 18, 2005
- PRTM Shows Results of Investigational Drug Survey
March 14, 2005
- ＜Special Comtribution＞
March 7, 2005
- ＜Special Comtribution＞
March 7, 2005
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…